pharmeasy
4 ARTICLES
Decoding PharmEasy’s latest down round logic
The proposed rights issue, at a 90% valuation cut, makes one thing clear: it’s the investors who are calling the shots here.
07 Jul 2023
PharmEasy might need to sell Thyrocare
The diagnostics firm was acquired at great cost, but is unable to support PharmEasy’s core online pharmacy business.
01 Feb 2023
PharmEasy is staring at hard times
The online drugs and medical services startup made some costly acquisitions in a bid to pull off an IPO at a high valuation. That plan may be coming unstuck.
21 Jul 2022
PharmEasy: A difficult prognosis
Parent API Holdings seems to be banking on FOMO to raise public money at 500% more than what it was valued at nine months ago.
22 Nov 2021